Diamond Hill Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Diamond Hill Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-547	Closed	-$134K	–	165
2019 Q4	$134K	Sell	547 -2,504	-82%	-$632K	﹤0.01%	157
2019 Q3	$1.05M	Sell	3,051 -1,027	-25%	-$558K	0.01%	139
2019 Q2	$3.75M	Buy	4,078 +1,785	+78%	+$2.19M	0.02%	136
2019 Q1	$3.66M	Buy	2,293 +2,032	+779%	+$3.66M	0.02%	134
2018 Q4	$487K	Buy	261 +94	+56%	+$205K	﹤0.01%	157
2018 Q3	$393K	Buy	167 +52	+45%	+$161K	﹤0.01%	156
2018 Q2	$395K	Hold	115	–	–	﹤0.01%	161
2018 Q1	$326K	Sell	115 -41	-26%	-$123K	﹤0.01%	160
2017 Q4	$401K	Buy	+156	New	+$443K	﹤0.01%	160

Other funds holding ACOR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Diamond Hill Capital Management's ACOR Position: Q1 2020 in Review

Diamond Hill Capital Management sold out of Acorda Therapeutics (ACOR) in Q1 2020, closing a stake of 547 shares — an estimated $134K sold.

Diamond Hill Capital Management first reported a position in ACOR in Q4 2017 and held it in 9 quarters. The position peaked at $3.75M in Q2 2019. 106 funds tracked by Wall St. Rank hold ACOR as of Q1 2020.

Diamond Hill Capital Management reported no remaining Acorda Therapeutics position as of Q1 2020 after selling out during the quarter.
Diamond Hill Capital Management sold 547 Acorda Therapeutics shares in Q1 2020, an estimated $134K.
Diamond Hill Capital Management first reported a position in Acorda Therapeutics in Q4 2017 and held it in 9 quarters.
Diamond Hill Capital Management's Acorda Therapeutics position peaked at $3.75M in Q2 2019.
106 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2020.

Based on Diamond Hill Capital Management's 13F filing for Q1 2020, filed 5 May 2020.